Relapse of Type a β-Lactamase-Producing Staphylococcus aureus Native Valve Endocarditis during Cefazolin Therapy: Revisiting the Issue

Clinical Infectious Diseases

Volumn 37, Issue 9, 2003, Pages 1194-1198

  Nannini, Esteban C ^a   Singh, Kavindra V ^a   Murray, Barbara E ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAMASE; BETA LACTAMASE A; CEFALOTIN; CEFAMANDOLE; CEFAZOLIN; GENTAMICIN; METICILLIN; NAFCILLIN; RIFAMPICIN; UNCLASSIFIED DRUG; VANCOMYCIN;

ADULT; ANTIBIOTIC SENSITIVITY; AORTA VALVE DISEASE; ARTICLE; BACTERIAL ENDOCARDITIS; BACTERIAL GENE; BACTERIAL GROWTH; BACTERIAL REGROWTH; BACTERICIDAL ACTIVITY; BETA LACTAMASE GENE; BLOOD CULTURE; CASE REPORT; DNA SEQUENCE; DRUG DEGRADATION; DRUG HYDROLYSIS; DRUG INACTIVATION; HUMAN; INOCULATION; INOCULUM SIZE; MALE; MINIMUM INHIBITORY CONCENTRATION; PRIORITY JOURNAL; RELAPSE; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; TIME TO KILL CURVE;

ANTI-BACTERIAL AGENTS; BETA-LACTAMASES; CEFAZOLIN; ENDOCARDITIS, BACTERIAL; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; RECURRENCE; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS;

EID: 0242407418     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/379021     Document Type: Article

References (26)

1. Richmond MH. Immunological techniques for studying β-lactamases. Methods Enzymol 1975; 43:86-100.
2. Kernodle DS, McGraw PA, Stratton CW, Kaiser AB. Use of extracts versus whole-cell bacterial suspensions in the identification of Staphylococcus aureus β-lactamase variants. Antimicrob Agents Chemother 1990; 34:420-5.
3. Kernodle DS, Stratton CW, McMurray LW, Chipley JR, McGraw PA. Differentiation of β-lactamase variants of Staphylococcus aureus by substrate hydrolysis profiles. J Infect Dis 1989; 159:103-8.
4. Voladri RK, Kernodle DS. Characterization of a chromosomal gene encoding type B β-lactamase in phage group II isolates of Staphylococcus aureus. Antimicrob Agents Chemother 1998; 42:3163-8.
5. Zygmunt DJ, Stratton CW, Kernodle DS. Characterization of four β-lactamases produced by Staphylococcus aureus. Antimicrob Agents Chemother 1992; 36:440-5.
6. Quinn EL, Pohlod D, Madhavan T, Burch K, Fisher E, Cox F. Clinical experiences with cefazolin and other cephalosporins in bacterial endocarditis. J Infect Dis 1973; 128(Suppl):S386-9.
7. Bryant RE, Alford RH. Unsuccessful treatment of staphylococcal endocarditis with cefazolin. JAMA 1977; 237:569-70.
8. Kaye D, Hewitt W, Remington JS, Turck M. Cefazolin and Staphylococcus aureus endocarditis. JAMA 1977; 237:2601.
9. NCCLS. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard. 6th ed. NCCLS document M7-A6. Wayne, PA: NCCLS, 2003.
10. Kernodle DS, Classen DC, Stratton CW, Kaiser AB. Association of borderline oxacillin-susceptible strains of Staphylococcus aureus with surgical wound infections. J Clin Microbiol 1998; 36:219-22.
11. Bennett JV, Brodie JL, Benner EJ, Kirby WM. Simplified, accurate method for antibiotic assay of clinical specimens. Appl Microbiol 1966; 14:170-7.
12. Carrizosa J, Kobasa WD, Snepar R, Kaye KM, Kaye D. Cefazolin versus cephalothin in β-lactamase-producing Staphylococcus aureus endocarditis in a rabbit experimental model. J Antimicrob Chemother 1982; 9: 387-93.
13. Malathum K, Singh KV, Weinstock GM, Murray BE. Repetitive sequence-based PCR versus pulsed-field gel electrophoresis for typing of Enterococcus faecalis at the subspecies level. J Clin Microbiol 1998; 36:211-5.
14. Wilson K. Preparation of genomic DNA from bacteria. In: Ausubel FM, Brent R, Kingston RE, David DM, Scidman JG, Smith JA, Struhl K, eds. Current protocols in molecular biology. Brooklyn, NY: Green Publishing Associates, 1994:2.4.1-2.4.2.
15. Tomayko JF, Zscheck KK, Singh KV, Murray BE. Comparison of the β-lactamase gene cluster in clonally distinct strains of Enterococcus faecalis. Antimicrob Agents Chemother 1996; 40:1170-4.
16. Wang PZ, Novick RP. Nucleotide sequence and expression of the β-lactamase gene from Staphylococcus aureus plasmid pI258 in Escherichia coli, Bacillus subtilis, and Staphylococcus aureus. J Bacteriol 1987; 169: 1763-6.
17. Farrar WE Jr, Gramling PK. Antistaphylococcal activity and β-lactamase resistance of newer cephalosporins. J Infect Dis 1976; 133:691-5.
18. Cacoub P, Leprince P, Nataf P, et al. Pacemaker infective endocarditis. Am J Cardiol 1998; 82:480-4.
19. Reinarz JA, Kier CM, Guckian JC. Evaluation of cefazolin in the treatment of bacterial endocarditis and bacteremia. J Infect Dis 1973; 128 (Suppl):S392-6.
20. Kernodle DS, Classen DC, Burke JP, Kaiser AB. Failure of cephalosporins to prevent Staphylococcus aureus surgical wound infections. JAMA 1990; 263:961-6.
21. Goldman PL, Petersdorf RG. Importance of β-lactamase inactivation in treatment of experimental endocarditis caused by Staphylococcus aureus. J Infect Dis 1980; 141:331-7.
22. Tallan BM, Rouse M, Kernodle DS, Steckelberg JM, Henry NK, Wilson WR. Effect of quantity and location of Staphylococcus aureus β-lactamase on outcome of cephalosporin treatment of experimental endocarditis [abstract 363]. In: Program and abstracts of the 31st Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago). Washington, DC: American Society for Microbiology, 1991:159.
23. Chapman SW, Steigbigel RT. Staphylococcal β-lactamase and efficacy of β-lactam antibiotics: in vitro and in vivo evaluation. J Infect Dis 1983; 147:1078-89.
24. Bruns W, Keppeler H. Extracellular and membrane-bound β lactamase of Staphylococcus aureus: their importance for the expression of penicillin resistance. J Med Microbiol 1987; 23:133-9.
25. Gold JA, McKee JJ, Ziv DS. Experience with cefazolin: an overall summary of pharmacologic and clinical trials in man. J Infect Dis 1973; 128(Suppl):S415-21.
26. Wilson WR, Karchmer AW, Dajani AS, et al. Antibiotic treatment of adults with infective endocarditis due to streptococci, enterococci, staphylococci, and HACEK microorganisms. American Heart Association. JAMA 1995; 274:1705-13.